Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharma The FDA will allow patients with MASH to undergo Wegovy treatment, hampering the only other company with an approved MASH drug.
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease FDA approves Novo Nordisk's Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects lower 2025 sales growth.
Billionaire Investor Buys Google And This Gold Miner Stock John Paulson's hedge fund discloses the purchase of 9,000 shares of Alphabet.
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Beats Q2 2025 Revenue Estimates and Narrows Losses on Strong Rezdiffra Sales Madrigal Pharmaceuticals (MDGL) beats Q2 2025 revenue estimates with $212.8M, driven by strong Rezdiffra sales, narrowing losses. Stock rises 12.8% pre-market.
European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug Rezdiffra wins CHMP backing for conditional EU approval in MASH with fibrosis; decision from European Commission expected in August.
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment, Rezdiffra.
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.
